AU2019340767B9 - Triazolo-pyrimidine compounds and uses thereof - Google Patents
Triazolo-pyrimidine compounds and uses thereof Download PDFInfo
- Publication number
- AU2019340767B9 AU2019340767B9 AU2019340767A AU2019340767A AU2019340767B9 AU 2019340767 B9 AU2019340767 B9 AU 2019340767B9 AU 2019340767 A AU2019340767 A AU 2019340767A AU 2019340767 A AU2019340767 A AU 2019340767A AU 2019340767 B9 AU2019340767 B9 AU 2019340767B9
- Authority
- AU
- Australia
- Prior art keywords
- triazolo
- pyrimidin
- methyl
- amine
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/105220 | 2018-09-12 | ||
| CN2018105220 | 2018-09-12 | ||
| PCT/CN2019/105591 WO2020052631A1 (en) | 2018-09-12 | 2019-09-12 | Triazolo-pyrimidine compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2019340767A1 AU2019340767A1 (en) | 2021-04-08 |
| AU2019340767B2 AU2019340767B2 (en) | 2024-11-14 |
| AU2019340767B9 true AU2019340767B9 (en) | 2024-12-05 |
Family
ID=69778192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019340767A Active AU2019340767B9 (en) | 2018-09-12 | 2019-09-12 | Triazolo-pyrimidine compounds and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10858365B2 (https=) |
| EP (1) | EP3849983A4 (https=) |
| JP (2) | JP7572353B2 (https=) |
| KR (1) | KR102841843B1 (https=) |
| CN (3) | CN111635408B (https=) |
| AR (1) | AR116315A1 (https=) |
| AU (1) | AU2019340767B9 (https=) |
| BR (1) | BR112021004774A2 (https=) |
| CA (1) | CA3111869A1 (https=) |
| MX (1) | MX2021002998A (https=) |
| TW (1) | TWI820209B (https=) |
| WO (1) | WO2020052631A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066410B2 (en) * | 2017-03-24 | 2021-07-20 | 3100 Central Expressway Llc | Fused triazolo-pyrimidine compounds having useful pharmaceutical application |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
| EP3911324A4 (en) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
| EP3911323A4 (en) | 2019-01-18 | 2022-11-16 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US20210061809A1 (en) * | 2019-08-26 | 2021-03-04 | Incyte Corporation | Triazolopyrimidines as a2a / a2b inhibitors |
| WO2021156439A1 (en) | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
| CN120022278A (zh) * | 2023-11-22 | 2025-05-23 | 英诺湖医药(杭州)有限公司 | 用于治疗癌症的化合物 |
| CN117865963B (zh) * | 2023-12-15 | 2026-02-24 | 上海凌凯科技股份有限公司 | 一种嘧啶酮衍生物的合成方法及嘧啶酮衍生物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4195729B2 (ja) * | 1997-03-24 | 2008-12-10 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| JPWO2002079204A1 (ja) | 2001-03-28 | 2004-07-22 | 協和醗酵工業株式会社 | ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| PE20030739A1 (es) | 2001-11-30 | 2003-08-28 | Schering Corp | Antagonistas del receptor de adenosina a2a |
| EP1544200A1 (en) | 2002-09-24 | 2005-06-22 | Kyowa Hakko Kogyo Co., Ltd. | 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE |
| CN110214012B (zh) * | 2017-01-20 | 2023-05-09 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的唑嘧啶 |
| CN109963854B (zh) * | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
| PL3611174T3 (pl) * | 2017-04-07 | 2022-08-08 | Medshine Discovery Inc. | Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a |
| CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| BR122023024273A2 (pt) * | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| CN112105617B (zh) * | 2018-04-28 | 2022-04-05 | 南京明德新药研发有限公司 | 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法 |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
-
2019
- 2019-09-11 AR ARP190102589A patent/AR116315A1/es unknown
- 2019-09-11 TW TW108132759A patent/TWI820209B/zh active
- 2019-09-12 JP JP2021513827A patent/JP7572353B2/ja active Active
- 2019-09-12 CA CA3111869A patent/CA3111869A1/en active Pending
- 2019-09-12 CN CN202010656938.4A patent/CN111635408B/zh active Active
- 2019-09-12 CN CN202010657655.1A patent/CN112279852B/zh active Active
- 2019-09-12 WO PCT/CN2019/105591 patent/WO2020052631A1/en not_active Ceased
- 2019-09-12 BR BR112021004774-3A patent/BR112021004774A2/pt unknown
- 2019-09-12 AU AU2019340767A patent/AU2019340767B9/en active Active
- 2019-09-12 KR KR1020217010809A patent/KR102841843B1/ko active Active
- 2019-09-12 CN CN201980006436.2A patent/CN111601809A/zh active Pending
- 2019-09-12 EP EP19859380.8A patent/EP3849983A4/en active Pending
- 2019-09-12 MX MX2021002998A patent/MX2021002998A/es unknown
-
2020
- 2020-06-24 US US16/910,334 patent/US10858365B2/en active Active
- 2020-09-22 US US17/027,740 patent/US11629147B2/en active Active
-
2024
- 2024-06-13 JP JP2024096058A patent/JP2024123079A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021004774A2 (pt) | 2021-08-03 |
| TW202024089A (zh) | 2020-07-01 |
| JP2022500402A (ja) | 2022-01-04 |
| CN111635408B (zh) | 2022-07-22 |
| MX2021002998A (es) | 2021-05-14 |
| CN111635408A (zh) | 2020-09-08 |
| US11629147B2 (en) | 2023-04-18 |
| TWI820209B (zh) | 2023-11-01 |
| CN111601809A (zh) | 2020-08-28 |
| JP7572353B2 (ja) | 2024-10-23 |
| CN112279852A (zh) | 2021-01-29 |
| KR20210075996A (ko) | 2021-06-23 |
| WO2020052631A1 (en) | 2020-03-19 |
| US20210009600A1 (en) | 2021-01-14 |
| US10858365B2 (en) | 2020-12-08 |
| JP2024123079A (ja) | 2024-09-10 |
| AU2019340767A1 (en) | 2021-04-08 |
| EP3849983A1 (en) | 2021-07-21 |
| CA3111869A1 (en) | 2020-03-19 |
| AU2019340767B2 (en) | 2024-11-14 |
| AR116315A1 (es) | 2021-04-21 |
| KR102841843B1 (ko) | 2025-08-01 |
| US20200331918A1 (en) | 2020-10-22 |
| CN112279852B (zh) | 2023-01-17 |
| EP3849983A4 (en) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019340767B9 (en) | Triazolo-pyrimidine compounds and uses thereof | |
| AU2019323035B2 (en) | Pyrazine compounds and uses thereof | |
| KR102632018B1 (ko) | Fgfr 저해제로서의 이환식 복소환 | |
| AU2023202886B2 (en) | Adenosine receptor antagonist compounds | |
| RU2802866C9 (ru) | Соединения триазоло-пиримидина и их применение | |
| RU2802866C2 (ru) | Соединения триазоло-пиримидина и их применение | |
| HK40045058B (en) | Triazolo-pyrimidine compounds and uses thereof | |
| HK40027808A (en) | Triazolo-pyrimidine compounds and uses thereof | |
| HK40045058A (en) | Triazolo-pyrimidine compounds and uses thereof | |
| HK40027808B (en) | Triazolo-pyrimidine compounds and uses thereof | |
| HK40026664A (en) | Triazolo-pyrimidine compounds and uses thereof | |
| RU2809631C2 (ru) | Пиразиновые соединения и их применения | |
| EA049133B1 (ru) | Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2а/a2b | |
| BRPI0719333A2 (pt) | Midazotriazinas e imidazopirimidinas como inbidores de cinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| FGA | Letters patent sealed or granted (standard patent) |